References
- Pasquini R, Cortes JE, Kantarjian HM, Joske D, Meillon LA, Zernovak O, et al.. Survey of the frontline treatment and management of chronic myeloid leukemia (CML) in a real-word setting: the 3rd annual update of the worldwide observational registry collecting longitudinal data on management of chronic myeloid leukemia patients (The WORLD CML Registry). Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 1695.
- Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al.. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35.
- Pasquini MC, Wang Z, Horowitz M, Gale RP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplant for blood and bone marrow disorders. In: , Cecka J M, Terazaki P I, ed, editors. Clinical transplants 2010. Los Angeles (CA): The Terasaki Foundation Laboratory; 2011. p. 87–105.
- Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, et al.. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2011.
- Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al.. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70.
- Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al.. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–9.
- Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A, et al.. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer. 2011;116(21):4991–5000.
- Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al.. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–20.
- Ruiz-Arguelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, Gutierrez-Riveroll KI, Rangel-Malo R, Gutierrez-Aguirre CH, et al.. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant. 2008;42(1):23–8.
- Bittencourt H, Funke V, Fogliatto L, Magalhaes S, Setubal D, Paz A, et al.. Imatinibmesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant. 2008;42(9):597–600.